Fact: There are presently no treatments to effectively slow or halt disease progression of ALS
Current treatment of ALS is aimed at symptomatic relief, prevention of complications and maintenance of maximum optimal function and optimal quality of life.
Most of this, in the later stages, requires nursing management of a patient who is alert but functionally quadriplegic with intact sensory function and bedridden.
Riluzole, the first treatment to alter the course of ALS, was approved by the FDA in late 1995. This antiglutamate drug was shown scientifically to prolong the life of persons with ALS by at least a few months.
More recent studies suggest Riluzole slows the progress of ALS, allowing the patient more time in the higher functioning states when their function is less affected by ALS.
Reports from three separate patient databases described long range experience with Riluzole. All three reports suggest a trend of increasing survival with Riluzole over time.
More studies are needed to confirm these database observations. The trend appears to indicate that longer periods of time than those used in the Riluzole clinical trials may be needed to see the long-term survival advantage of the drug.
Click here for more information on the drug. Rilutek® (Riluzole) is manufactured by Sanofi-Aventis Pharmaceuticals, who sponsor a Patient Assistance Program that helps patients who qualify receive the drug.
Many private health plans cover the cost of Riluzole. Further information on Riluzole coverage through Medicare Prescription Drug Benefit can be found in the Advocacy pages of this website.
The RASCALS Foundation is doing everything it can year-round to spread the message about Lou Gehrig’s disease. In reality, this is everybody’s disease—and there is so much more to do.
In addition to raising awareness, we also work to raise much-needed financial resources for the ALS community.
You can make a secure online donation via PayPal here, or mail your gift here:
P.O. Box 31834
St. Louis, MO 63131
How is your money used?
On your behalf, RASCALS has made annual contributions to ALS research centers so they can keep searching for answers and treatments.
The Neuromuscular and Clinical Neurophysiology Services Group of St. Louis University was a 2013 recipient.
HIGHER EDUCATION SCHOLARSHIPS
The financial burdens of ALS are as horrific as the disease itself. So each year we present college scholarships to members of families affected by ALS.
The scholarship awards are based in part on applicants’ original essays that address “How ALS Has Influenced My Life.”
RASCALS GIVES 100%
The Robert A. Stehlin Campaign for ALS (R.A.S.C.A.L.S.) is an all-volunteer 501(c)(3) charity.
You can be sure that 100% of every dollar that you donate goes to building awareness, treatment research and development, plus ALS family assistance.
This is ALS Awareness Month. Please make it a point to tell someone about ALS, also known as Lou Gehrig’s disease.
Thank you for all you do.